Research Correspondence

DOI: 10.4244/EIJ-D-23-00561

Quantitative flow ratio for the prediction of coronary events after percutaneous coronary intervention

Shigetaka Kageyama1,2, MD; Neil O'Leary1,2, PhD; Pruthvi Chenniganahosahalli Revaiah1,2, MD; Kai Ninomiya1,2, MD; Shinichiro Masuda1,2, MD; Nozomi Kotoku1,2, MD; Nidhi Ilancheran2; Scot Garg3, MD, PhD; Emma Harte1,2, PhD; Grainne Ni Bheolain1,2, MSc; Johan H.C. Reiber4, PhD; Shengxian Tu5, PhD; Azfar Zaman6, MD, BSc; Manel Sabaté7, MD, PhD; Helge Möllmann8, MD, PhD; Faisal Sharif1, MD, PhD; Julien Lemoine9, MD; Adrian Wlodarczak10, MD; Yoshinobu Onuma1,2,11, MD, PhD; Patrick W. Serruys1,2,11, MD, PhD; on behalf of the Multivessel TALENT trial

The Multivessel TALENT trial is an ongoing randomised controlled trial comparing 2 drug-eluting stents in patients with de novo three-vessel disease without left main disease1. The study design mandates an offline assessment of quantitative flow ratio (QFR) pre-percutaneous coronary intervention (PCI) to prospectively identify which lesions should be treated. The rationale of this study lies in the post hoc analysis of the SYNTAX II trial, which established that a post-PCI QFR ≥0.91 was the optimal cut-off for a lower risk of 2-year vessel-oriented composite endpoints (VOCE). ClinicalTrials.gov: NCT04390672.

The current study was a vessel-based analysis using the post-PCI QFR from the first 775 patients randomised in the Multivessel TALENT study and was conducted before event adjudication commenced to forecast the rate of VOCE at 2 years for the entire population.

The details of the Multivessel TALENT trial design have been previously published1. The powered secondary endpoint is a superiority comparison in the per-protocol analysis of VOCE, a composite of vessel-related cardiovascular death, vessel-related myocardial infarction, and clinically and physiologically indicated target vessel revascularisation at 24 months post-procedure1.

...
Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 1
Jan 1, 2024
Volume 20 Number 1
View full issue


Key metrics

On the same subject

Clinical Research

10.4244/EIJ-D-21-00176 Feb 18, 2022
Outcomes of quantitative flow ratio-based percutaneous coronary intervention in an all-comers study
Zhang R et al
free

10.4244/EIJV17I4A46 Jul 20, 2021
Beyond ischaemia: is there a place for physiologic and anatomic evaluations of coronary lesions?
Montalescot G and Zeitouni M
free

Editorial

10.4244/EIJ-E-23-00031 Aug 7, 2023
Quantitative flow ratio and cardiovascular risk: paralleling the FFR ischaemic continuum
Kern M
free
Trending articles
187.45

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
170.15

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
159.45

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
127.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
108.75

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved